相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Birt-Hogg-Dube syndrome-associated renal cell carcinoma: Histopathological features and diagnostic conundrum
Mitsuko Furuya et al.
CANCER SCIENCE (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial
Toni K. Choueiri et al.
JAMA ONCOLOGY (2020)
Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease
Hiroki Ishihara et al.
CANCER SCIENCE (2020)
Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date
Olivier Bylicki et al.
ONCOTARGETS AND THERAPY (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells
Masao Nakajima et al.
CANCER SCIENCE (2019)
Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses Than Seen in the Eosinophilic Subtype
Riuko Ohashi et al.
CANCERS (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity?
Shuji Mikami et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Erhao Zhang et al.
MOLECULAR CANCER (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Emerging Cellular Therapies for Cancer
Sonia Guedan et al.
Annual Review of Immunology (2018)
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Maria Georganaki et al.
FRONTIERS IN IMMUNOLOGY (2018)
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
L. M. A. Aparicio et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Alwin G. Schuller et al.
CLINICAL CANCER RESEARCH (2015)
Papillary renal cell carcinoma: A review of the current therapeutic landscape
Giulia Courthod et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Hepatocyte growth factor and Met in drug discovery
Katsuya Sakai et al.
JOURNAL OF BIOCHEMISTRY (2015)
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
Connie P. M. Duong et al.
MOLECULAR IMMUNOLOGY (2015)
Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model
Stephanie Du Four et al.
ONCOIMMUNOLOGY (2015)
Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation
Huaqin Yuan et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
J. Jean Cui
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
Lisha Wang et al.
MOLECULAR CANCER (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
G. T. Gibney et al.
ANNALS OF ONCOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of Disease
Raghunandan Vikram et al.
RADIOGRAPHICS (2009)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature
Bruce M. Fenton et al.
CANCER RESEARCH (2007)
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging
Lisa J. Wilmes et al.
MAGNETIC RESONANCE IMAGING (2007)
Genetic basis of cancer of the kidney: Disease specific approaches to therapy
WM Linehan et al.
CLINICAL CANCER RESEARCH (2004)
Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma
ME Sanders et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Biological significance of c-met over expression in papillary renal cell carcinoma
P Sweeney et al.
JOURNAL OF UROLOGY (2002)
Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases
B Delahunt et al.
HUMAN PATHOLOGY (2001)
分享论文
